Rejection of Tamibarotene's Chinese Imported-Drug Registration Application and Response to Potential Resubmission
A theme concerning the rejection of the Chinese imported-drug registration application for tamibarotene during NMPA review, giving rise to the possibility of resubmission with additional clinical trials and data.
Companies1How many companies write about this.
Threads3One company can carry more than one thread here.